Lyell Immunopharma, Inc. (NASDAQ:LYEL) Shares Purchased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 352.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 29,137 shares of the company’s stock after acquiring an additional 22,701 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Lyell Immunopharma were worth $57,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in LYEL. Public Employees Retirement System of Ohio boosted its stake in Lyell Immunopharma by 109.7% during the third quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock worth $40,000 after buying an additional 14,229 shares during the last quarter. Profund Advisors LLC grew its holdings in shares of Lyell Immunopharma by 20.0% in the third quarter. Profund Advisors LLC now owns 73,442 shares of the company’s stock valued at $108,000 after purchasing an additional 12,225 shares during the period. Citigroup Inc. increased its position in Lyell Immunopharma by 20.0% during the third quarter. Citigroup Inc. now owns 193,739 shares of the company’s stock worth $285,000 after purchasing an additional 32,225 shares during the last quarter. Exchange Traded Concepts LLC increased its position in Lyell Immunopharma by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 82,956 shares of the company’s stock worth $161,000 after purchasing an additional 21,036 shares during the last quarter. Finally, Ieq Capital LLC purchased a new position in Lyell Immunopharma during the third quarter worth about $121,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Lyell Immunopharma Price Performance

NASDAQ:LYEL opened at $2.09 on Monday. Lyell Immunopharma, Inc. has a 52 week low of $1.32 and a 52 week high of $3.97. The stock’s fifty day moving average is $2.16 and its two-hundred day moving average is $1.95. The company has a market capitalization of $531.07 million, a P/E ratio of -2.25 and a beta of -0.56.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. Lyell Immunopharma had a negative return on equity of 32.67% and a negative net margin of 180,486.14%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $4.96 million. Sell-side analysts anticipate that Lyell Immunopharma, Inc. will post -0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright dropped their price target on shares of Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, February 29th.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.